<DOC>
	<DOCNO>NCT01863849</DOCNO>
	<brief_summary>To assess immunogenicity single intramuscular injection Fluval AB suspension injection ( trivalent , seasonal influenza vaccine , active ingredient content : 15 μgHA/0.5mL seasonal A/H1N1 , A/H3N2 B influenza antigen ) , measure haemagglutination inhibition ( HI ) test .</brief_summary>
	<brief_title>Tolerability Immunogenicity Study Fluval AB Suspension Injection</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Adult person age 18 59 year , elderly person age ≥60 year sexes , mentally competent ; Are good health ( determine vital sign exist medical condition ) stable medical condition . Subjects exclude know adequately treat clinically significant organ systemic disease ( e.g . asthma diabetes ) , , opinion investigator , significance disease compromise subject 's participation study ; Female volunteer age 1859 year ( i.e . participant childbearing potential ) negative result urine pregnancy test prior vaccination agree use acceptable contraception method abstinence throughout trial become pregnant duration study ; Capability participant understand comply plan study procedure ; Participants provide write Informed Consent ( IC ) prior initiation study procedure ; Absence existence exclusion criterion . Pregnancy , breast feeding positive urine pregnancy test baseline prior vaccination . Female subject able bear child willing use acceptable contraception method duration study . Known hypersensitivity egg , chicken protein , thiomersal , formaldehyde , gentamycin , ciprofloxacin , neomycin , vancomycin component vaccine ; History GuillainBarré syndrome ; History neurological symptom sign , anaphylactic shock follow administration vaccine ; Serious disease , cancer , autoimmune disease , advance arteriosclerotic disease , complicate diabetes mellitus , acute progressive hepatic disease , acute progressive renal disease , congestive heart failure ; Immunosuppressive therapy within 36 month prior vaccination ; Concomitant corticosteroid therapy , include highdose inhaled corticosteroid ; Receipt immunostimulants ; Receipt parenteral immunoglobulin , blood product and/or plasma derivate within 3 month prior vaccination ; Suspected known HIV , HBV HCV infection ; Acute disease and/or axillary temperature ≥37oC within 3 day prior vaccination ; Vaccine therapy within 4 week prior vaccination ; Influenza vaccination ( kind ) within 6 month prior vaccination ; Experimental drug therapy within 4 week prior vaccination ; Concomitant participation another clinical study ; Any condition , opinion investigator , may interfere evaluation study ; Past current psychiatric disease volunteer upon judgement investigator may effect objective decisionmaking volunteer ; Alcohol drug abuse participant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>uncontrolled ,</keyword>
	<keyword>open ,</keyword>
	<keyword>multi-centre</keyword>
	<keyword>immunogenicity tolerability</keyword>
	<keyword>two group accord age ( 18-59 year ≥60 year )</keyword>
</DOC>